Rocket Doctor AI raised $3.26 million in 12% debt this month. In the same stretch, it signed a network agreement that touches roughly 60 million consumers. Only one of those numbers required diluting existing shareholders.
A Five-Channel Network Deal in California
Rocket Doctor AI Inc. (CSE: AIDR) (OTC: AIRDF) (Frankfurt: 939), a physician-led AI healthcare platform, said on August 18 that its wholly owned subsidiary Rocket Doctor Inc. entered into a strategic provider network agreement covering five channels in California, according to the company’s release on GlobeNewswire. The channels are commercial healthcare, Medicare Advantage, workers’ compensation, auto medical, and a complementary category, all through a single partner rather than five separate contracts.
The network itself serves more than 700 health plans, over 100,000 employers, and roughly 60 million consumers, with about 1.4 million contracted providers. The agreement took effect retroactively on July 1 and runs an initial one-year term with automatic annual renewals. Rocket Doctor frames the workers’ compensation and auto medical channels as new ground, markets it hadn’t previously had contracted access to in California.
A String of Similar Deals, Not a One-Off
This isn’t the first network expansion Rocket Doctor has announced this year. It signed a New York in-network deal covering 100,000 additional members on August 11, added over 2 million members through a California insurer in March, added 175,000 California members in January, and closed a value-based primary care agreement in June. None of these releases disclose a dollar figure tied to the expanded access. Membership counts describe the size of the network Rocket Doctor can now bill through, not confirmed patient volume or revenue.
$3.26 Million Raised in Two Tranches of 12% Debentures
Rocket Doctor also closed a private placement of unsecured convertible debentures this month. The first tranche, $2,269,000, closed August 6. The second, $992,000, closed August 17, bringing the total to $3,261,000. The debentures carry 12% annual interest, paid at maturity, which falls 12 months after each issuance.
Holders can convert principal and accrued interest into units at $0.70 Canadian ($0.50 US) per unit, each unit made up of one common share and one warrant. Rocket Doctor’s stock has traded in the roughly $0.59 to $0.65 range around these announcements, meaning the conversion price sits above where the stock actually trades right now. The company paid eligible arm’s length finders a combined $57,540 in cash fees on the deal, and the securities issued carry the standard four-month-and-one-day hold period.
What Rocket Doctor AI Does
The company builds AI-powered tools that let physicians run virtual or hybrid practices, centered on something it calls the Global Library of Medicine, a clinical decision support system built with input from physicians worldwide. Rocket Doctor says its platform has supported more than 350 doctors and 750,000 patient visits to date.
Other Disclosures Worth Knowing
Rocket Doctor has paid for stock promotion this year. It engaged Danayi Capital Corp. in January for USD$125,000 to run digital marketing and online ads, and it joined B2i Digital’s Featured Company Program in August for a USD$21,375 cash fee covering roughly three months of promotional activity. Neither firm is disclosed as holding an ownership stake in the company beyond what it might acquire in the ordinary course.
What to Watch Next
The debentures mature roughly a year from issuance, meaning Rocket Doctor either repays $3.26 million in cash next August or the stock needs to climb enough to make conversion at $0.70 attractive to holders. On the commercial side, whether any of this year’s network expansions show up as actual revenue growth in Rocket Doctor’s next quarterly results is the more useful test than the announcements themselves.
Sources
- GlobeNewswire: Rocket Doctor Enters New Strategic Network Agreement in California to Expand Access Across Multiple U.S. Healthcare Channels, August 18, 2026
- GlobeNewswire (via TipRanks): Rocket Doctor AI Raises C$3.26 Million in Oversubscribed Convertible Debenture Financing, August 17, 2026
- GlobeNewswire: Rocket Doctor Expands In-Network Access for More Than 100,000 Additional Eligible Members in New York, August 11, 2026
Editorial Disclosure
This article is based on primary company disclosures from Rocket Doctor AI Inc., distributed via GlobeNewswire on August 18, August 17, and August 11, 2026, along with the company’s prior releases on its debenture offering and paid promotional engagements. The security discussed is Rocket Doctor AI Inc. (CSE: AIDR) (OTC: AIRDF) (Frankfurt: 939). aktiego.com has not received any compensation from Rocket Doctor AI, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication.
Rocket Doctor AI has issued a large number of similarly worded network-expansion press releases throughout 2026. None of the releases cited in this article disclose a dollar figure, patient volume, or revenue impact tied to the expanded network access; membership counts describe network size, not confirmed utilization. The company has also disclosed two separate paid stock promotion engagements in 2026, with Danayi Capital Corp. and B2i Digital, both cash-fee arrangements. The convertible debentures discussed carry a 12% annual interest rate and a conversion price of $0.70 Canadian per unit, above the stock’s recent trading range; readers should treat conversion as uncertain rather than assumed. Market capitalization and stock price figures cited are approximate and sourced from third-party financial data providers, not the company’s own disclosures, and have varied meaningfully across sources and dates.
This is a speculative investment carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
